Cesca Therapeutics Granted Third U.S. Patent Relating to Its Proprietary SurgWerks™ Platform
October 18 2016 - 6:00AM
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based
regenerative medicine company, today announced that the United
States Patent & Trademark Office (USPTO) has granted the
Company the third of a family of patent applications related to its
proprietary methods for the treatment of ischemic cardiovascular
disorders, such as critical limb ischemia (CLI) and acute
myocardial infarction (AMI). The patent (numbered 9,439,930)
protects key components of Cesca’s SurgWerks™ technology platform,
relating to cell compositions & methods, designed for the rapid
delivery of autologous regenerative cell therapies in a
point-of-care environment.
“This patent covers critical methods for the
rapid infusion of autologous bone marrow derived stem &
progenitor cells, integral steps in our proprietary SurgWerks™
platform based treatment technique,” said Dalip Sethi, Ph.D.,
Cesca’s Director of Clinical Research. “Our growing portfolio of
SurgWerks™ platform patents underpins our approach to the treatment
of cardiovascular diseases with rapid, point-of-care
procedures.”
Cesca has more than 30 issued patents covering
its market leading technology for the concentration and cryogenic
storage of umbilical cord blood derived stem & progenitor
cells. With its expanding portfolio of intellectual property
covering key components of the SurgWerks™ platform, the Company
seeks to bring the same level of innovation to autologous, bone
marrow derived stem cell treatments for cardiovascular and
orthopedic disorders at the patient’s bedside.
About Cesca Therapeutics
Inc.
Cesca Therapeutics Inc.
(www.cescatherapeutics.com) is engaged in the research,
development, and commercialization of cellular therapies and
delivery systems for use in regenerative medicine. The Company is a
leader in the development and manufacture of automated blood and
bone marrow processing systems that enable the separation,
processing and preservation of cell and tissue therapeutics. These
include:
- The
SurgWerks™
System (in
development) - a proprietary system comprised of the SurgWerks™
Processing Platform, including devices and analytics, and
indication-specific SurgWerks™ Procedure Kits for use in
regenerative stem cell therapy at the point-of-care for vascular
and orthopedic diseases.
- The CellWerks™
System (in development) - a proprietary cell processing
system with associated analytics for intra-laboratory preparation
of adult stem cells from bone marrow or blood.
- The AutoXpress®
System (AXP®) - a proprietary automated device and
companion sterile disposable for concentrating hematopoietic stem
cells from cord blood.
- The MarrowXpress™
System (MXP™) - a derivative product of the AXP and its
accompanying sterile disposable for the isolation and concentration
of hematopoietic stem cells from bone marrow.
- The BioArchive®
System - an automated cryogenic device used by cord blood
banks for the cryopreservation and storage of cord blood stem cell
concentrate for future use.
- Manual bag sets for use in
the processing and cryogenic storage of cord blood.
Forward-Looking Statements and Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995
This press release includes statements of future
expectations and other forward-looking statements that are within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based on management’s current views and assumptions, speak only as
of the date hereof and are subject to change.
Forward-looking statements can often be identified by words
such as “anticipates,” “belief,” “intend,” “may,” “could,” “would,”
“potential,” “continue,” and similar expressions and include, but
are not limited to, statements regarding research, development and
commercialization of the SurgWerks™ system, patent applications and
patent grants. These forward-looking statements are not guarantees
of future results and are subject to known and unknown risks and
uncertainties that could cause actual results, performance or
events to differ materially and adversely from those expressed or
implied in such statements. A more complete description of risks
that could cause actual events to differ from the outcomes
predicted by these forward-looking statements is set forth under
the caption "Risk Factors" in our Annual Report on Form 10-K, in
our Quarterly Reports on Form 10-Q, and in other reports filed with
the Securities and Exchange Commission from time to time, and you
should also consider each of those factors when evaluating the
forward-looking statements. We undertake no obligation to revise or
update publicly any forward-looking statements for any reason,
except as required by law.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
lroth@theruthgroup.com / tbui@theruthgroup.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024